In this Review, Teixeira et al. discuss emerging strategies for developing and improving engineered-cell therapies. They outline progress from ex vivo engineered autologous cells to in vivo reprogramming, advances in delivery systems and the remaining transla…
Engineered cell therapies are transforming precision medicine by enabling real-time, context-responsive interventions that act upon disease-specific cues. Inspired by the success of CAR-T cells in oncology, next-generation platforms are being developed using diverse immune cells and stem cells to address a broader spectrum of diseases. These living therapeutics harness synthetic gene circuits to induce targeted cytotoxicity, to modulate the secretion of effector proteins or to coordinate both functions in response to endogenous signals or externally delivered molecular and physical triggers. Ex vivo engineering of autologous cells remains the norm, but challenges in scalability, cost and accessibility are fuelling efforts towards allogeneic products and in vivo reprogramming. Advances in targeted delivery — using viral vectors, mRNA-loaded nanoparticles and virus-like particles — are expanding the toolkit for direct programming of cells within the body. This Review discusses emerging strategies for engineering human cells with therapeutic functions, highlighting modular control systems, delivery innovations and the translational hurdles that lie ahead.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
Prices may be subject to local taxes which are calculated during checkout
Източник: Nature.com
Тази статия е автоматично импортирана от външен източник. За оригиналното съдържание на пълната статия, моля посетете източника.